Press Release

PAI Pharma Expands Unit-Dose and Liquid Medicine Offerings by Acquiring VistaPharma

PAI Pharma

November 03, 2022

PAI Pharma is pleased to announce the acquisition of VistaPharm—a privately held, healthcare company that offers generic pharmaceuticals and over the counter products for hospitals, retail pharmacies, and the specialized clinical setting. As the largest liquid developer and manufacturer in the U.S. and the leader in unit-dose and liquid medicines, PAI Pharma is now positioned to offer an expanded portfolio of 250+ product NDCs including 50+ retail items and nearly 100 unit-dose SKUs, all with dedicated customer service support.

Kurt Orlafski, CEO of PAI Pharma, remarks “Our mission is to participate in the creation of healthier lives by exceeding the expectations of those we serve. The acquisition of VistaPharm allows us to offer our customers more products to help meet their patients’ needs. We remain the ultimate partner of choice because we consistently, reliably, affordably deliver medications every time.”

Our mission is to participate in the creation of healthier lives by exceeding the expectations of those we serve. The acquisition of VistaPharm allows us to offer our customers more products to help meet their patients’ needs. We remain the ultimate partner of choice because we consistently, reliably, affordably deliver medications every time.

Kurt Orlafski, CEO of PAI Pharma

Since 2001, VistaPharm has been dedicated to improving the lives of patients struggling with addiction. Now a PAI Pharma Company, they will remain the leading distributor and only full-line wholesaler of pharmaceutical products to opioid treatment program (OTP) clinics. Their product portfolio will continue to offer a wide range of addiction treatment medications, including different dosage forms and strengths of methadone, buprenorphine, and naloxone-based products. To learn more about VistaPharm’s offerings for OTP clinics, please visit https://vistapharm.com/opioidproducts.html.